Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

5.29
+0.26005.17%
Pre-market: 5.19-0.1000-1.89%08:00 EDT
Volume:132.98K
Turnover:694.57K
Market Cap:16.89M
PE:-0.23
High:5.33
Open:5.05
Low:5.04
Close:5.03
52wk High:67.50
52wk Low:4.11
Shares:3.19M
Float Shares:3.14M
Volume Ratio:1.62
T/O Rate:4.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.3991
EPS(LYR):-36.5197
ROE:-273.88%
ROA:-111.74%
PB:3.03
PE(LYR):-0.14

Loading ...

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

GlobeNewswire
·
Yesterday

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

GlobeNewswire
·
Sep 05

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

GlobeNewswire
·
Sep 03

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

GlobeNewswire
·
Aug 27

Cellectar Biosciences Q2 EPS $(3.39) Beats $(3.98) Estimate

Benzinga
·
Aug 14

Cellectar Biosciences Inc - to Pursue Nda Submission for Iopofosine I 131

THOMSON REUTERS
·
Aug 14

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire
·
Aug 14

Cellectar Biosciences Inc expected to post a loss of $3.90 a share - Earnings Preview

Reuters
·
Aug 12

Cellectar Biosciences Inc expected to post a loss of $3.90 a share - Earnings Preview

Reuters
·
Aug 09

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

GlobeNewswire
·
Aug 07

CEO James V. Caruso Reports Acquisition of Cellectar BioSciences Inc. Common Shares

Reuters
·
Jul 03

Cellectar BioSciences COO Jarrod Longcor Reports Acquisition of Common Shares

Reuters
·
Jul 03

Cellectar Biosciences Closes $6.9 Million Public Offering

MT Newswires Live
·
Jul 03

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

GlobeNewswire
·
Jul 03

Top Midday Decliners

MT Newswires Live
·
Jul 02

Cellectar Biosciences Shares Drop After $6M Public Offering Prices

Dow Jones
·
Jul 01

Cellectar BioSciences Announces One-for-Thirty Reverse Stock Split

Reuters
·
Jun 26

BRIEF-Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer

Reuters
·
Jun 24

Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24

MT Newswires Live
·
Jun 19

Cellectar BioSciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 14